mProX™ Human BTLA Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Immune Checkpoint Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human BTLA Stable Cell Line (S01YF-1023-PY173). Click the button above to contact us or submit your feedback about this product.
Skyler Johnson (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Peyton Jones (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 BTLA and HVEM are an axis in regulating cell proliferation.
The effects of simultaneous BTLA and HVEM expression knockdown in NCI-H1299 cells were initially explored. KD efficiencies were confirmed by immunoblot, revealing increased cell proliferation in all KD cells compared to the control group. However, no further increase in proliferation was observed when both BTLA and HVEM were simultaneously knocked down, as opposed to either BTLA or HVEM KD alone (left panels). Similarly, p-ERK1/2 levels were enhanced upon KD of either BTLA or HVEM expression, but the simultaneous double KD of both did not lead to further enhancement (left panels). Given that BTLA and HVEM were expressed in a subpopulation of cancer cells, it was hypothesized that cell growth could be further inhibited through simultaneous overexpression of both BTLA and HVEM. Subsequently, cells with simultaneous overexpression of BTLA and HVEM exhibited significantly reduced proliferation compared to those overexpressing either BTLA, HVEM, or the control (Right panels). Correspondingly, simultaneous transfection with both BTLA and HVEM significantly suppressed p-ERK1/2 levels compared to the overexpression of either BTLA or HVEM alone.
Ref: Cheng, Tian-You, et al. "Tumor cell-intrinsic btla receptor inhibits the proliferation of tumor cells Via Erk1/2." Cells 11.24 (2022): 4021.
Pubmed: 36552785
DOI: 10.3390/cells11244021
Research Highlights
Wu, Zhisheng. et al. "Comprehensive analysis of cuproptosis genes and cuproptosis-related genes as prognosis factors in esophageal squamous cell carcinoma." Genomics, 2023.
Esophageal squamous cell carcinoma (ESCC) is a prevalent and harmful form of cancer with a low five-year survival rate. To identify potential therapeutic targets, the characteristics of cuproptosis genes (CUGs) in ESCC were investigated. The expression patterns of 10 CUGs (FDX1, LIPT1, LIAS, DLAT, DLD, PDHA1, PDHB, GLS, MTF1, and CDKN2A) were analyzed to pinpoint relevant targets for ESCC. Weighted correlation network analysis (WGCNA) was used to identify CUG-related genes (CRGs). Seven differentially expressed genes were identified, with stage III upregulation of DLAT and N0+N1 upregulation of LIPT1. High expression of CDKN2A and PDHA1 correlated with better overall survival, while low expression of LIAS correlated with better clinical outcomes. WGCNA revealed three key modules associated with FDX1, DLAT, and LIPT1. A risk score model was created using CRGs (BTLA, CT47A1, and PRRX1) to predict survival and prognosis for ESCC patients. A cuproptosis score based on CUGs and a corresponding nomogram accurately predicted the prognosis of ESCC patients for potential diagnostic use. Furthermore, inhibition of CDKN2A by milciclib showed potential in suppressing proliferation and migration of ESCC cells. In summary, these CUGs and CRGs are crucial in the development and progression of ESCC, highlighting their potential as therapeutic targets.
Wu, Zhisheng. et al. "Comprehensive analysis of cuproptosis genes and cuproptosis-related genes as prognosis factors in esophageal squamous cell carcinoma." Genomics, 2023.
Pubmed:
37866660
DOI:
10.1016/j.ygeno.2023.110732
Lê, Hélène, et al. "In vitro vascularized immunocompetent patient-derived model to test cancer therapies." iScience (2023): 108094.
The described study presents a tumoroid model, derived from patient samples (PDTs), for use in lung oncology precision medicine. The model utilizes microvasculature from human adipose tissue and peripheral blood mononuclear cells (PBMCs) from the patient, resulting in a physiologically relevant tumor microenvironment. Ten patients at varying stages of tumor progression were involved in the study. Within two weeks, a vascularized and immune-infiltrated PDT model was successfully created, meeting the requirements of therapeutic decision making. Histological and transcriptomic analyses confirmed that key features of the original tumor were replicated. The 3D tumor model was used to evaluate the effectiveness of antiangiogenic therapy and platinum-based chemotherapy. Antiangiogenic therapy was found to effectively decrease vascular endothelial growth factor-A expression, while chemotherapy reduced levels of lymphocyte activation gene-3 protein, B and T lymphocyte attenuator, and other inhibitory receptors on T cells.
Lê, Hélène, et al. "In vitro vascularized immunocompetent patient-derived model to test cancer therapies." iScience (2023): 108094.
Pubmed:
37860774
DOI:
10.1016/j.isci.2023.108094
